Societe Generale upgraded Fresenius Medical to Buy from Hold with a EUR 71 price target. The analyst says reverse engineering the firm’s upgraded discounted free cash flow valuation implies that at current levels the share price is discounting that Fresenius Medical will cease to exist in the mid-2030s. The analyst tells investors to “exploit the mispricing.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FMS:
- Fresenius Medical price target lowered to EUR 34 from EUR 46 at Deutsche Bank
- Fresenius Medical to sell Boston IVF fertility network, TRIO to IVI RMA
- Fresenius Medical price target raised to EUR 39 from EUR 38 at Barclays
- Fresenius Medical price target lowered to EUR 28 from EUR 32.10 at JPMorgan
- Fresenius Medical Care continues to execute on turnaround plan and raises 2023 earnings outlook due to strong operational performance in first nine months and solid business outlook for the fourth quarter